NCT04400201View on ClinicalTrials.gov

A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy

PHASE3CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

October 28, 2020

Study Completion Date

October 30, 2020

Conditions
Sedation
Interventions
DRUG

Remimazolam Tosilate

Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.

DRUG

Propofol

Intravenous injection at a dose of 1.5\~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0\~12 mg/kg/h for sedation maintenance

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04400201 - A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy | Biotech Hunter | Biotech Hunter